Search - tctmd.com

Displaying 1 - 20 of 306

Sort: Relevancy | Date

News Daily News

GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Daily News

Telemedicine May Adversely Impact Care Quality for HF Patients

Caitlin E. Cox

January 26, 2026

News Daily News

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

Caitlin E. Cox

December 31, 2025

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

Yael L. Maxwell

December 26, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

Todd Neale

November 14, 2025

News Conference News AHA 2025

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

Todd Neale

November 12, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Presentation TCT 2025

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

Presenter: Ahmed A. Mahmoud

October 28, 2025

Presentation TCT 2025

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

TCT 801: Comparative Efficacy and Safety of Beta Blockers Versus SGLT2 Inhibitors in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA)

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Priyesh Thakurathi

October 27, 2025

Presentation TCT 2025

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

Presenter: Salman Zahid

October 27, 2025

Presentation TCT 2025

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Presentation TCT 2025

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

News Daily News

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

Todd Neale

October 07, 2025

Advertisement

GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Telemedicine May Adversely Impact Care Quality for HF Patients

Year in Review: Structural Heart in 2025 Features EARLY TAVR, Tricuspid Nuance, Mitral Gains

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

DARE-AF Dapagliflozin Fails to Reduce AF Burden After Catheter Ablation

What’s Going to Be Hot at AHA 2025?

TCT 498: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention

TCT 494: Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis

TCT 801: Comparative Efficacy and Safety of Beta Blockers Versus SGLT2 Inhibitors in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA)

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content